Are palpitations a contraindication to phentermine in a patient with a history of pulmonary embolism who is taking apixaban?

Are Palpitations a Contraindication to Phentermine?

No, palpitations are not an absolute contraindication to phentermine, but they represent a commonly reported adverse effect that warrants careful consideration, particularly in patients with cardiovascular disease history such as pulmonary embolism. 1

Key Clinical Context

The 2022 AGA guidelines explicitly list palpitations as a commonly reported adverse effect of phentermine, not as a contraindication 1. However, the guidelines are clear about when phentermine should be avoided:

Absolute Avoidance Situations:

• History of cardiovascular disease (which includes pulmonary embolism) 1
• Uncontrolled hypertension 1
• Untreated hyperthyroidism (due to arrhythmia concerns) 1
• Use with or within 14 days of MAO inhibitors 1

Critical Decision Point for This Patient

In your specific patient with a history of pulmonary embolism on apixaban, phentermine should be avoided entirely 1. The guideline recommendation states phentermine "should be avoided in patients with a history of cardiovascular disease" 1, and pulmonary embolism falls squarely within this category.

Why This Matters:

1. Sympathomimetic cardiovascular effects: Phentermine causes adrenergic stimulation that can increase heart rate and potentially blood pressure 1

2. Documented arrhythmia risk: Case reports demonstrate phentermine can trigger supraventricular tachycardia 2 and atrial fibrillation 3 even in previously healthy individuals

3. Pulmonary hypertension concerns: There is documented association between phentermine and pulmonary hypertension 4, which is particularly concerning in someone with prior PE

4. No interaction with apixaban itself: The apixaban FDA label does not list specific interactions with phentermine 5, and apixaban is appropriate for PE treatment 6, 7, 8, 9

Clinical Algorithm

If patient is already experiencing palpitations:

• Do NOT initiate phentermine
• The combination of pre-existing palpitations + PE history = unacceptable cardiovascular risk

If patient has no current palpitations but has PE history:

• Still avoid phentermine per guideline recommendations 1
• Consider alternative weight loss medications with better cardiovascular safety profiles (semaglutide, liraglutide, naltrexone-bupropion with monitoring)

Monitoring requirements if phentermine were used (not recommended here):

• Blood pressure and heart rate monitoring periodically 1
• Immediate discontinuation if palpitations, chest pain, or dyspnea develop

Common Pitfall to Avoid

Do not be reassured by the fact that palpitations are "just a common side effect." In the context of prior PE, even common sympathomimetic effects carry heightened risk. The recent case report of phentermine-associated MI 10 underscores that cardiovascular complications can occur even in younger patients, particularly when risk factors are present.

Bottom line: Choose a different anti-obesity medication for this patient. The cardiovascular risk profile makes phentermine inappropriate regardless of whether palpitations are currently present.